Case Law[2025] ZAGPJHC 745South Africa
Medtronic (Africa) (Pty) Limited v Capital Endovascular (Pty) Limited and Another (2022/046095) [2025] ZAGPJHC 745 (5 August 2025)
Headnotes
Summary: Arbitration – Arbitration Act 42 of 1965 – award, making settlement agreement an Award of the Arbitrator in terms of Arbotration Foundation of SA’s rules – application to have award made an order of court granted in terms of s 31(1) of the Arbitration Act – application for specific performance in terms of settlement agreement – respondent disputing the terms of settlement agreement – interpretation of contract – purposive, textual and contextual interpretation to be applied.
Judgment
begin wrapper
begin container
begin header
begin slogan-floater
end slogan-floater
- About SAFLII
About SAFLII
- Databases
Databases
- Search
Search
- Terms of Use
Terms of Use
- RSS Feeds
RSS Feeds
end header
begin main
begin center
# South Africa: South Gauteng High Court, Johannesburg
South Africa: South Gauteng High Court, Johannesburg
You are here:
SAFLII
>>
Databases
>>
South Africa: South Gauteng High Court, Johannesburg
>>
2025
>>
[2025] ZAGPJHC 745
|
Noteup
|
LawCite
sino index
## Medtronic (Africa) (Pty) Limited v Capital Endovascular (Pty) Limited and Another (2022/046095) [2025] ZAGPJHC 745 (5 August 2025)
Medtronic (Africa) (Pty) Limited v Capital Endovascular (Pty) Limited and Another (2022/046095) [2025] ZAGPJHC 745 (5 August 2025)
Download original files
PDF format
RTF format
make_database: source=/home/saflii//raw/ZAGPJHC/Data/2025_745.html
sino date 5 August 2025
REPUBLIC OF SOUTH
AFRICA
IN THE HIGH COURT OF
SOUTH AFRICA
GAUTENG DIVISION,
JOHANNESBURG
(1) NOT REPORTABLE
(2) NOT OF INTREST TO
OTHER JUDGES
CASE
NO
:
2022-046095
DATE
:
5 August
2025
In the matter between:
MEDTRONIC
(AFRICA) (PTY) LIMITED
Applicant
and
CAPITAL
ENDOVASCULAR (PTY) LIMITED
First Respondent
AFRICAN HEALTHCARE
INVESTMENT
SOLUTIONS
(PTY) LIMITED
(
formerly
MANIPAL AFRICA (PTY)
LIMITED)
Fifth Respondent
Neutral
Citation
:
Medtronic (Africa) v Capital
Endovascular and Another (2022-046095)
[2025] ZAGPJHC ---
(5
August 2025)
Coram:
Adams J
Heard
:
22 April 2025
Delivered:
5 August 2025 – This judgment was handed down
electronically by circulation to the parties' representatives by
email, by being
uploaded to
CaseLines
and by release to
SAFLII. The date and time for hand-down is deemed to be 11:30 on
5 August 2025.
Summary:
Arbitration –
Arbitration Act 42 of 1965
– award, making settlement agreement an Award of the Arbitrator
in terms of Arbotration Foundation of SA’s rules –
application to have award made an order of court granted in terms of
s 31(1)
of the
Arbitration Act – application
for specific
performance in terms of settlement agreement – respondent
disputing the terms of settlement agreement –
interpretation of
contract – purposive, textual and contextual interpretation to
be applied.
Counterapplication to
have the settlement agreement rectified – respondent alleges
that the intention of the parties was to
agree on a particular amount
– dispute decided in favour of the applicant on the basis of
the principles relating to the
interpretation of contracts –
Application granted and
counterapplication dismissed.
ORDER
(1)
The Arbitration Award dated 11 July 2022 by
the Arbitrator, Mr Christopher Loxton SC, and handed down / published
by him on the
same date, being 11 July 2022, be and is hereby
made an Order of this Court.
(2)
The first respondent is ordered to comply
with the settlement agreement concluded between it and the applicant
on 29 June 2022,
read with addendum 1 thereto dated 11 July 2022
(‘the settlement agreement’).
(3)
The first respondent shall pay to the
applicant the capital amount of R21 million, together with
interest on the said sum of
R21 million at the prescribed legal rate
of interest of 8.25% per annum, calculated from 22 July 2022 to
date of final payment.
(4)
The first respondent shall pay the
applicant’s costs of this opposed application, including the
costs of two Counsel, one
being Senior Counsel (where so employed),
on scale ‘C’ of the applicable tariff provided for in the
Uniform Rules of
Court.
(5)
The first respondent’s
counterapplication for rectification of the settlement agreement be
and is hereby dismissed with costs.
(6)
The first respondent shall pay the
applicant’s costs of the opposed counterapplication, such costs
to include the costs consequent
upon the utilisation of two Counsel,
one being Senior Counsel (where so employed), on scale ‘C’
of the applicable tariff
provided for in the Uniform Rules of Court.
(7)
It be and is hereby declared that the
second respondent has indemnified the first respondent for any and
all claims made by the
applicant against the first respondent under
the settlement agreement concluded between the parties on 29 June and
11 July 2022
(‘the settlement agreement’).
(8)
The second respondent is liable to the
first respondents for any and all amounts which the first respondent
is ordered to pay to
the applicant by this Court under the case
number 2022-046095.
JUDGMENT
Adams J:
[1].
On 21 January 2016, the applicant (‘Medtronic’) and the
first respondent (‘Capital Endovascular’) concluded
a
so-called Strategic Co-operation Agreement, in terms of which
inter
alia
the first respondent purchased medical equipment from the
applicant. In terms of the dispute resolution provision (clause 19(5)
to (10)) of the said agreement, the parties agreed that any
unresolved dispute arising out of or in connection with the Strategic
Co-operation Agreement would be referred to arbitration under the
auspices of the Arbitration Foundation of Southern Africa (‘AFSA’).
[2].
During 2021 such a dispute as envisaged by clause 19(5) to (10)
indeed arose between Medtronic and Capital Endovascular. It was
alleged by Medtronic that it was owed amounts totalling ZAR66 224 636
by Capital Endovascular in respect of goods sold
and delivered and
services rendered, which Capital Endovascular had failed to pay
timeously. On 26 May 2021, Medtronic referred
the said dispute to
arbitration. Mr Christopher Loxton SC, Senior Counsel at the
Johannesburg Bar, was duly appointed as the Arbitrator
to adjudicate
the dispute.
[3].
During April 2022, the parties commenced settlement negotiations in
an endeavour to settle the dispute referred to arbitration.
On 24
April 2022, as evidenced by undisputed email correspondence between
the representatives of the parties, they reached agreement
on the
settlement terms. The respondents, so the applicant avers, were to
pay it the settlement amount of R48 million (excluding
VAT). By 11
July 2022 the agreement of settlement between Medtronic, Capital
Endovascular and the second respondent (‘Africa
Healthcare’),
had been reduced to writing in terms of a written settlement
agreement and an addendum thereto, which were
signed for and on
behalf of Medtronic by a Mr Loganathan Naidoo and Capital
Endovascular by a Mr Mahendren Moodley, who was,
at the relevant
time an officer of Africa Healthcare. The written settlement
agreement provided that same was to be made an award
of the
Arbitrator, which was done by agreement between all of the parties,
being Medtronic and Capital Endovascular and Africa
Healthcare.
[4].
In this opposed application, which came before me as a Special Motion
on 22 April 2025, the Medtronic applies
to
have the award of the Arbitrator made an order of this court.
Medtronic also applies for judgment against Capital Endovascular
and
African Healthcare for the balance of the capital amount of the
award, together with interest thereon and costs of suit.
Capital
Endovascular
opposes
the application primarily on the basis that the settlement agreed to
by it was for payment of the capital amount of R32
million (exclusive
of VAT) and not for payment of R48 million, as claimed by Medtronic.
The aforegoing is evidenced, so Capital
Endovascular contends, by the
fact that at one place in the written settlement agreement the amount
of R32 million is expressly
mentioned in words, although it is so
that the amount of R48 million is reference in numbers. This, so
Medtronic avers, was clearly
a patent error and the intention of the
parties have always and inevitably been that the respondents, jointly
and severally, were
to pay it (Medtronic) R48 million plus VAT.
African Healthcare filed a notice of intention to
oppose but has failed to file any answering papers. Medtronic has
proceeded against
it separately on an unopposed basis.
[5].
Therefore, in issue in this
application is simply whether
Capital Endovascular
had agreed to pay to
Medtronic R48 million (VAT exclusive) in settlement of the dispute
between them. I am therefore required to
interpret the agreement
concluded between the parties on the basis of the principles
applicable to the interpretation of contracts.
I interpose here to
note that a number of other defences are also raised by Capital
Endovascular, which I will deal with in due
course.
[6].
There is also a ‘counterapplication’
launched
by Capital Endovascular for rectification of the settlement agreement
that forms the subject-matter of the main application.
Capital
Endovascular asks that the agreement be rectified to reflect the
settlement amount as R32 million plus VAT, as against
R48 million.
The result of this counterapplication would axiomatically follow on
my finding relating to the main application. In
other words, in the
event of me finding for the applicant in the interpretation of the
settlement agreement, then it follows that
the counterapplication
should be dismissed. Capital Endovascular also applies for a
declarator of an indemnification by African
Healthcare in favour of
Capital Endovascular for any and all claims by Medtronic against
Capital arising under the settlement agreement.
This application is
unopposed by African Healthcare and I accordingly intend granting an
order by default against it.
[7].
The issues in this matter are to be decided against the factual
backdrop, the important facts being by and large common cause.
I deal
with the facts in paragraphs which follow as and when I deal with a
discussion and an analysis of the matter.
[8].
The
dramatis
personae
in this matter are: (a) Medtronic and Capital Endovascular, who were
the two parties to the Strategic Cooperation Agreement; (b)
African
Healthcare, which was interposed by Capital Endovascular in the
arbitration proceedings to settle the dispute with Medtronic;
(c) Mr
Logan Naidoo (‘Mr Naidoo’) is the sole director and
shareholder of Capital Endovascular and he is the one who
signed the
Strategic Cooperation Agreement and settlement agreement on behalf of
Capital; and (d) Mr Mahendren Moodley (‘Mr
Moodley’), who
is a director of African Healthcare and who was given a proxy and
power of attorney by Capital Endovascular
to represent it and to
settle the arbitration.
[9].
As I have already
indicated, it is common cause that by 24 April 2022 the dispute
between Medtronic Africa and Capital Endovascular,
which formed the
subject of the Arbitration, was settled by these two parties and
Africa Healthcare on the basis that Capital Africa
and Africa
Healthcare would pay to Medtronic Africa R48 million plus 15% VAT
(R7.2 million) = R55.2 million in full and final settlement
of
Medtronic Africa’s claim against Capital Africa. About the
aforegoing there can be no doubt. This is borne out by an email
communication dated 22 April 2022 from Medtronic Africa to Mr Moodley
on behalf of Capital Africa and Africa Healthcare in which
the
following offer is made:
‘
*
Our revised offer is a full settlement of
ZAR
48m + VAT
.
·
For avoidance
of doubt, the amount above
includes
interest on delayed payments
(we applied approx 1.00% per month instead of 1.50% per month as a
final gesture of goodwill).
·
We are
prepared to
bear
our own legal expenses
(we received the legal expenses breakdown from our counsel and it
amounts to ZAR 2.5m – this is only FYl).
·
Settlement to
be effected to Medtronic as a
single
payment
without
delay
.
·
This offer is
final
and valid only on the premise that we receive a
written
acceptance
from yourselves (as incoming investors) and Mr Naidoo (as current
owner) in the
next
24 hours
with a commitment
to
sign the (tri-party) settlement agreement early next week
(no later than Tuesday COB)
·
… … …’
.
(Emphasis as per original communiqué).
[10].
On 24 April 2022, Mr
Moodley responded per return email as follows on behalf of Capital
Endovascular and Africa Healthcare:
‘
Thank
you for your note. The final amount below is acceptable.
Thank
you for the effort in closing this.
We
are happy with the same.
Let's
discuss the paperwork tomorrow and close out the same.’
[11].
As the saying goes,
so far so good. The matter had been settled. The difficulty arose
when on 28 June 2022 Mr Moodley sent a scanned
settlement agreement
to Mr Kourieh (the official at Medtronic, who was intimately involved
on behalf of Medtronic in the settlement
negotiations), which
settlement agreement indicated the settlement amount as being R48
million in numbers and R32 million in words.
It was signed on behalf
of Capital Endovascular by Mr Naidoo and by Mr Moodley on behalf
of Africa Healthcare.
[12].
On 8 July 2022 the
attorneys for Medtronic Africa sent an email to Messrs Naidoo and
Moodley, attaching the final settlement agreement,
which clearly and
unequivocally provided for a settlement amount of R48 million. On the
same date, the said attorneys addressed
a letter to the Arbitrator in
which he stated that Medtronic will seek an award on the terms of the
settlement agreement on Monday,
11 July 2022, when the arbitration
was scheduled to resume. The email to the Arbitrator was also sent to
Mr Naidoo and Mr Moodley.
[13].
On Monday, 11 July
2022, the Arbitrator made the settlement agreement and an addendum
thereto an Award. The question to be considered
is therefore whether
the R32 million in words in the agreement initially signed by Messrs
Naidoo and Moodley was simply a typographical
error, which did not
detract from the intention of the parties to agree a settlement
amount of R48 million (VAT excluded).
[14].
Subsequently, Capital
Endovascular and/or Africa Healthcare made payment of an amount of
R34.2 million to Medtronic, leaving, according
to Medtronic Africa, a
balance of R21 million outstanding, which it is claiming is
these proceedings. Capital Africa alleges
that it has complied with
its obligations under the settlement agreement as the settlement
amount has been paid in full.
[15].
Deciding
the aforegoing issue requires an interpretation of the contract
concluded between the relevant parties. In that regard,
it is so, as
submitted by Mr Bothma SC, who appeared on behalf of Medtronic, that
the interpretative exercise should be done on
the basis of the
principles enunciated by the Supreme Court of Appeal
[1]
,
which have become trite. The inevitable point of departure is the
language of the provision itself, read in context, having regard
to
the purpose of the provision and the background to the preparation
and production of the contract. The subsequent conduct of
the parties
is also relevant.
[16].
Medtronic submits
that on a proper interpretation of the settlement agreement with
reference to the factual matrix as alluded to
supra
,
the inescapable conclusion to be reached is that the parties agreed
to a settlement amount of R48 million. I agree with this submission.
It is common cause between the parties that an initial offer of R50
million (exclusive of VAT) was initially considered by the
parties.
Medtronic then presented a revised settlement proposal of R48
million, which Mr Moodley accepted on behalf of Capital
Endovascular
and Africa Healthcare. At no stage during any of the settlement
discussions is the R32 million mentioned by any of
the parties. The
rhetorical question to be asked is how the settlement discussions
relating to R48 million translate into a R32
million settlement.
[17].
Moreover, Mr Moodley
subsequently confirmed that the settlement amount was in fact R48
Million and that the reference to R32 million
in words was an error.
The simple fact of the matter is that there is no evidence whatsoever
that either party proposed, or that
the parties ultimately agreed, a
settlement amount of R32 million. This sum appears to have been
plugged out of the air opportunistically
by Capital Endovascular
after the typographical error was discovered by it.
[18].
I therefore conclude
that the settlement agreement concluded between the parties, properly
and purposively interpreted in context,
provided for a settlement sum
of R48 million plus value added tax. I reach the same conclusion if
one is to regard the dispute
between the parties as a factual one.
All things considered, and having regard to the undisputed evidence
before me as elaborated
upon above, it can safely be said that the
version of Capital Endovascular can and should be rejected on the
papers as being untenable
and far-fetched.
[19].
Capital Endovascular
also contends that Mr
Moodley lacked the necessary authority to act on its behalf in the
conclusion of the settlement agreement.
The case on behalf of Capital
Endovascular is that Mr Moodley was mandated to negotiate, but not to
conclude, the settlement agreement,
and that the consent of the
company was required on the terms and conditions of the settlement.
[20].
There is no merit in
this contention – none whatsoever. An unfettered power of
attorney was provided by Capital Endovascular
to Medtronic, which was
transmitted by Mr Naidoo directly to Medtronic. Quite clearly, in the
power of attorney, Mr Moodley was
mandated not only to negotiate, but
also to settle the dispute between Medtronic and Capital
Endovascular. Mr Moodley clearly did
that.
[21].
In any event, as
submitted by Mr Bothma SC, it is trite that a principal in the
position of Capital Endovascular cannot by way of
alleged private
instructions to Mr Moodley, as its representative, curtail the
latter's authority as far as Medtronic as the third
party is
concerned. Accordingly, the alleged limitations or restrictions do
not assist Capital Endovascular at all in this matter.
Moreover, at a
factual level, there is no evidence whatsoever proffered that Capital
Endovascular did not approve the settlement
amount of R48 million but
only approved an amount of R32 million. That, in my view, spells the
end of that defence. On the evidence
before me, I accept that at no
point was Mr Moodley mandated to settle the matter at R32 million. On
the contrary, he represented
that he was duly authorised, initially
to propose a settlement amount of R50 million plus VAT following
alignment with Mr Naidoo,
which he did, and later to accept
Medtronic’s revised settlement offer of R48 million plus VAT,
which he did on behalf of
both Capital Endovascular and Africa
Healthcare.
[22].
In light of my
aforegoing findings, it follows that the rectification application by
Capital Endovascular should fail. A case for
rectification is not
made out by Capital Endovascular. The antecedent negotiations between
the parties show that the settlement
agreement was for the amount of
R48 million. There can be no doubt that there was no agreement
between Medtronic and Capital Endovascular
for an amount of R32
million. It is only these two choices that are open to the Court, R48
million or R32 million. The documentary
evidence shows that the
settlement agreement was for the amount of R48 million.
[23].
Capital Endovascular
furthermore contends that the Award of the Arbitrator is
unenforceable. In the event of non-compliance with
the settlement
agreement, so the contention on behalf of Capital Endovascular goes,
Medtronic could either enforce the agreement
by seeking an Order
directing payment or proceed with arbitration for the full value due
to it. Accordingly, the Arbitrator’s
Award was not final and
left Medtronic with options due to it. There is not merit in this
submission. I agree with the contention
on behalf of Medtronic that
the aforegoing submission by Capital Endovascular is nonsensical. The
simple point is this. The fact
that Medtronic had options available
to it does not detract from the validity of the settlement agreement.
In any event, Medtronic
has elected to enforce the settlement
agreement against the respondents in accordance with the
Arbitration
Act.
[24
].
Moreover, it is trite
that
section 31(1)
of the
Arbitration Act, 42 of 1965
empowers a
Court, on application by Medtronic, to make the Award an Order of
Court.
[25].
I therefore conclude
that Medtronic has made out a clear case for the relief sought and
for an order making the award granted by
the Arbitrator an Order of
Court. There is no merit in the claim for rectification or the
defences set out by Capital Endovascular.
[26].
Accordingly, the
applicant’s application to have the Arbitrator’s award
made an Order of Court should be granted and
the first respondent’s
rectification application falls to be dismissed with costs,
Costs
[27].
The
general rule in matters of costs is that the successful party should
be given his costs, and this rule should not be departed
from except
where there are good grounds for doing so, such as misconduct on the
part of the successful party or other exceptional
circumstances. See:
Myers
v Abramson
[2]
.
[28].
I can think of no reason why I should deviate from
this general rule. The applicant should therefore be granted its
costs of its
main application, as well as the costs relating to the
first respondent’s counterapplication.
Order
[29].
In the result, I make the following order:
(1)
The Arbitration Award dated 11 July 2022 by
the Arbitrator, Mr Christopher Loxton SC, and handed down / published
by him on the
same date, being 11 July 2022, be and is hereby
made an Order of this Court.
(2)
The first respondent is ordered to comply
with the settlement agreement concluded between it and the applicant
on 29 June 2022,
read with addendum 1 thereto dated 11 July 2022
(‘the settlement agreement’).
(3)
The first respondent shall pay to the
applicant the capital amount of R21 million, together with
interest on the said sum of
R21 million at the prescribed legal rate
of interest of 8.25% per annum, calculated from 22 July 2022 to
date of final payment.
(4)
The first respondent shall pay the
applicant’s costs of this opposed application, including the
costs of two Counsel, one
being Senior Counsel (where so employed),
on scale ‘C’ of the applicable tariff provided for in the
Uniform Rules of
Court.
(5)
The first respondent’s
counterapplication for rectification of the settlement agreement be
and is hereby dismissed with costs.
(6)
The first respondent shall pay the
applicant’s costs of the opposed counterapplication, such costs
to include the costs consequent
upon the utilisation of two Counsel,
one being Senior Counsel (where so employed), on scale ‘C’
of the applicable tariff
provided for in the Uniform Rules of Court.
(7)
It be and is hereby declared that the
second respondent has indemnified the first respondent for any and
all claims made by the
applicant against the first respondent under
the settlement agreement concluded between the parties on 29 June and
11 July 2022
(‘the settlement agreement’).
(8)
The second respondent is liable to the
first respondents for any and all amounts which the first respondent
is ordered to pay to
the applicant by this Court under the case
number 2022-046095.
L R ADAMS
Judge of the High
Court
Gauteng Division,
Johannesburg
HEARD ON:
22 April 2025
JUDGMENT DATE:
5 August 2025 –
Judgment handed down electronically
FOR THE APPLICANT:
H C Bothma SC, with L
S Crow
INSTRUCTED BY:
DLA Piper South Africa
(RF) Inc, Sandown, Sandton
FOR
THE FIRST RESPONDENT:
I
Pillay SC, with I Veerasamy
INSTRUCTED
BY:
Maynard
Menon Govind Singh Inc, Westville, Durban, Kwazulu-Natal
FOR
THE SECOND RESPONDENT:
No
appearance
INSTRUCTED
BY:
No
appearance – Attorneys withdrew
[1]
Natal
Joint Municipal Pension Fund v Endumeni Municipality
2012
(4) SA 593
(SCA). Also see:
Capitec
Bank Holdings Ltd and Another v Coral Lagoon Investments 194 (Pty)
Ltd and Others
2022 (1) SA 100 (SCA).
[2]
Myers
v Abrahamson
1951(3)
SA 438 (C) at 455
sino noindex
make_database footer start
Similar Cases
Medtronic (Africa) (Pty) Limited v Capital Endovascular (Pty) Limited and Another (2022/046095) [2025] ZAGPJHC 1015 (15 October 2025)
[2025] ZAGPJHC 1015High Court of South Africa (Gauteng Division, Johannesburg)100% similar
Transmed South Africa Holdings (Pty) v Schaffner and Others (2023/084393) [2024] ZAGPJHC 482 (16 May 2024)
[2024] ZAGPJHC 482High Court of South Africa (Gauteng Division, Johannesburg)99% similar
Allmed Healthcare Professionals (Pty) Ltd v Gauteng Department of Health and Others (2023/77864) [2023] ZAGPJHC 1007 (8 September 2023)
[2023] ZAGPJHC 1007High Court of South Africa (Gauteng Division, Johannesburg)99% similar
Medicross Healthcare Group (Pty) Ltd v Linde and Associates (A2024/113909) [2025] ZAGPJHC 804; 2026 (1) SA 222 (GJ) (6 August 2025)
[2025] ZAGPJHC 804High Court of South Africa (Gauteng Division, Johannesburg)99% similar
Communication Genetics (Pty) Ltd v Schonenberger and Another (025959/2025) [2025] ZAGPJHC 338 (2 April 2025)
[2025] ZAGPJHC 338High Court of South Africa (Gauteng Division, Johannesburg)99% similar